Serimmune, a leader in understanding the functional antibody repertoire’s role in human disease, today announced that the company has received a research milestone payment from Merck (known as MSD outside the United States and Canada) under its ongoing discovery and development collaboration agreement.
GOLETA, Calif. – April 2,
2020 – Serimmune, a leader in
understanding the functional antibody repertoire’s role in human disease, today
announced that the company has received a research milestone payment from Merck
(known as MSD outside the United States and Canada) under its ongoing discovery
and development collaboration agreement.
"We are excited that Merck has been able to successfully apply
our proprietary platform to advance their preclinical efforts in infectious
diseases," said Noah Nasser, CEO of Serimmune. "Our Serum
Epitope Repertoire Analysis (SERA) platform and growing database of epitope
repertoires from more than 10,000 individuals is a valuable resource for
understanding the immune system’s role in disease.”
Under terms of the previously announced agreement,
Serimmune applied its SERA platform to clinical and preclinical specimens
provided by Merck. Merck will lead preclinical and clinical development and
commercialization of candidates identified from the collaboration. Serimmune is
eligible to receive research, development and regulatory milestone payments and
tiered royalties on sales of any products resulting from the collaboration.
Serimmune’s SERA
technology platform reveals the diverse antigens that stimulate immunity. Serimmune is using this platform to create a growing database that can be interrogated
to uncover disease information. The company is actively pursuing commercial
partnerships for the SERA platform and has a number of ongoing collaborations
with government, academic and commercial organizations.
About Serimmune
Serimmune is a leader in understanding the antibody
repertoire and is focused on identifying and exploiting the universe of
relationships between antibodies and antigens. The company’s Serum Epitope
Repertoire Analysis (SERA) technology platform
applies bacterial display peptide libraries, next generation sequencing,
machine learning and custom bioinformatics to reveal the many diverse antigens
stimulating immunity. Serimmune’s human immunity map is a growing database that can be
interrogated to uncover disease information for the development of multiplex diagnostics,
vaccines and therapeutics. The company was founded in 2014 and is backed by
investors such as Illumina Ventures, LabCorp, and Merck. For more information
visit www.serimmune.com